TP53 and cancer: It has exhibited strong antiproliferative activities, antitumor effects and has induced apoptosis in various cancers.27 In addition, MK-2206 is an orally active, selective and potent allosteric inhibitor of Akt; preclinical studies have demonstrated its efficacy in the treatment of various cancers.28 Here, we evaluated whether inhibition of PI3K/Akt signaling by BKM-120 and MK-2206 would affect the phosphorylation and activation of Akt in correlation with PTEN and P53.